ADIL
Adial Pharmaceuticals, Inc. [ADIL] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ADIL Stock Summary
Top 10 Correlated Stocks
ADIL
In the News
ADIL Financial details
Company Rating
Neutral
Market Cap
9.45M
Income
-5.11M
Revenue
0
Book val./share
2.45
Cash/share
1.7
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-0.33
Forward P/E
-
PEG
0.03
P/S
-
P/B
0.86
P/C
1.26
P/FCF
-0.28
Quick Ratio
1.26
Current Ratio
2.15
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-6.45
EPS next Y
-
EPS next Q
-
EPS this Y
-98.29%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-2.54%
-
-
-
-
SMA20
-
SMA50
100%
SMA100
-
Inst Own
7.83%
Inst Trans
0.94%
ROA
-211%
ROE
-233%
ROC
-3.85%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.77-14.0
52W High
-
52W Low
-
RSI
57
Rel Volume
0.02
Avg Volume
6.43M
Volume
142.76K
Perf Week
-7.73%
Perf Month
1.42%
Perf Quarter
5.39%
Perf Half Y
-28.09%
-
-
-
-
Beta
1.527
-
-
Volatility
0.26%, 0.48%
Prev Close
-7.33%
Price
2.15
Change
-4.02%
ADIL Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -21.8 | -21.79 | -26.12 | -317.81 | -5.44 | |
| Operating cash flow per share | -16.08 | -15.31 | -16.07 | -279.23 | -4.78 | |
| Free cash flow per share | -16.08 | -15.31 | -16.16 | -279.23 | -4.78 | |
| Cash per share | 17.2 | 8.83 | 8.15 | 99.9 | 1.98 | |
| Book value per share | 18.12 | 8 | 4.72 | 81.79 | 2.87 | |
| Tangible book value per share | 18.1 | 7.98 | 3.76 | 64.1 | 2.86 | |
| Share holders equity per share | 18.12 | 8 | 4.72 | 81.79 | 2.87 | |
| Interest debt per share | 0 | 0 | 0.35 | -9.43 | 0 | |
| Market cap | 23.74M | 21.19M | 50.19M | 220.33K | 2.65M | |
| Enterprise value | 16.97M | 16.79M | 44.38M | -3.57M | -177.21K | |
| P/E ratio | -2.76 | -1.95 | -2.58 | -0.02 | -0.34 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -3.75 | -2.78 | -4.2 | -0.02 | -0.39 | |
| PFCF ratio | -3.75 | -2.78 | -4.18 | -0.02 | -0.39 | |
| P/B Ratio | 3.33 | 5.32 | 14.31 | 0.07 | 0.65 | |
| PTB ratio | 3.33 | 5.32 | 14.31 | 0.07 | 0.65 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -2.08 | -1.54 | -2.8 | 0.26 | 0.03 | |
| EV to operating cash flow | -2.68 | -2.2 | -3.71 | 0.32 | 0.03 | |
| EV to free cash flow | -2.68 | -2.2 | -3.69 | 0.32 | 0.03 | |
| Earnings yield | -0.36 | -0.51 | -0.39 | -57.78 | -2.92 | |
| Free cash flow yield | -0.27 | -0.36 | -0.24 | -50.77 | -2.57 | |
| Debt to equity | 0 | 0 | 0.07 | 0.06 | 0 | |
| Debt to assets | 0 | 0 | 0.03 | 0.04 | 0 | |
| Net debt to EBITDA | 0.83 | 0.4 | 0.37 | 0.28 | 0.41 | |
| Current ratio | 14.24 | 3.41 | 2.37 | 2.67 | 4.9 | |
| Interest coverage | 0 | 0 | 0 | 22.76 | 0 | |
| Income quality | 0.74 | 0.7 | 0.62 | 0.88 | 0.97 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0.09 | 0.12 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.01 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | -1.17 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 94.27 | 62.6 | 52.66 | 764.76 | 18.73 | |
| ROIC | -1.15 | -2.73 | -4.77 | -3.61 | -1.23 | |
| Return on tangible assets | -1.12 | -1.98 | -2.87 | -2.53 | -1.64 | |
| Graham Net | 15.83 | 5.81 | 2.82 | 38.58 | 1.53 | |
| Working capital | 7.13M | 3.63M | 3.74M | 2.99M | 2.55M | |
| Tangible asset value | 7.13M | 3.98M | 2.8M | 2.57M | 4.08M | |
| Net current asset value | 7.13M | 3.63M | 2.49M | 2.32M | 2.55M | |
| Invested capital | 0 | 0 | 0.07 | 0.06 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 224.09K | 419.47K | 467.47K | 340.01K | 260.61K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 122.88K | 419.84K | 1.9K | 2.38K | 82.44K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0.19 | 0.15 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -1.2 | -2.72 | -5.54 | -3.89 | -1.9 | |
| Capex per share | 0 | 0 | -0.09 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -2.69 | -2.73 | 0.96 | -1.18 | -1.15 | |
| Operating cash flow per share | -1.64 | -2.17 | -1.67 | -1.18 | -0.73 | |
| Free cash flow per share | -1.64 | -2.17 | -1.67 | -1.18 | -0.73 | |
| Cash per share | 3.75 | 2.18 | 1.08 | 0.27 | 1.7 | |
| Book value per share | 3.07 | 1.36 | 2.93 | 1.98 | 2.45 | |
| Tangible book value per share | 2.41 | 0.69 | 2.93 | 1.98 | 2.45 | |
| Share holders equity per share | 3.07 | 1.36 | 2.93 | 1.98 | 2.45 | |
| Interest debt per share | -0.28 | 0.17 | 0 | 0 | 0 | |
| Market cap | 5.87M | 9.26M | 5.94M | 3.28M | 3.09M | |
| Enterprise value | 2.08M | 7.14M | 4.72M | 2.96M | 266.88K | |
| P/E ratio | -0.51 | -0.8 | 1.37 | -0.59 | -0.4 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -3.35 | -4.03 | -3.14 | -2.36 | -2.53 | |
| PFCF ratio | -3.35 | -4.03 | -3.14 | -2.36 | -2.53 | |
| P/B Ratio | 1.79 | 6.43 | 1.79 | 1.4 | 0.76 | |
| PTB ratio | 1.79 | 6.43 | 1.79 | 1.4 | 0.76 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -0.59 | -2.47 | -3.2 | -2.18 | -0.15 | |
| EV to operating cash flow | -1.19 | -3.11 | -2.49 | -2.13 | -0.22 | |
| EV to free cash flow | -1.19 | -3.11 | -2.49 | -2.13 | -0.22 | |
| Earnings yield | -0.49 | -0.31 | 0.18 | -0.42 | -0.62 | |
| Free cash flow yield | -0.3 | -0.25 | -0.32 | -0.42 | -0.4 | |
| Debt to equity | 0.06 | 0.13 | 0 | 0 | 0 | |
| Debt to assets | 0.04 | 0.05 | 0 | 0 | 0 | |
| Net debt to EBITDA | 1.07 | 0.73 | 0.82 | 0.23 | 1.58 | |
| Current ratio | 2.67 | 1.65 | 4.43 | 2.15 | 4.9 | |
| Interest coverage | 6.39 | 196.13 | 0 | 0 | 0 | |
| Income quality | 0.61 | 0.79 | 2.24 | 1.03 | 0.64 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.12 | 0.18 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 13.62 | 9.14 | 7.96 | 7.24 | 7.99 | |
| ROIC | -0.88 | -1.59 | 0.32 | -0.6 | -0.44 | |
| Return on tangible assets | -0.57 | -0.91 | 0.29 | -0.48 | -0.41 | |
| Graham Net | 1.45 | -0.14 | 1.16 | 0.04 | 1.31 | |
| Working capital | 2.99M | 1.17M | 1.59M | 607.31K | 2.55M | |
| Tangible asset value | 2.57M | 731.54K | 3.31M | 2.34M | 4.08M | |
| Net current asset value | 2.32M | 502.82K | 1.59M | 607.31K | 2.55M | |
| Invested capital | 0.06 | 0.13 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 368.64K | 543.64K | 175K | |
| Average payables | 336.02K | 461.99K | 320.92K | 96.81K | 104.66K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 2.28K | 3.01K | 71.3K | 52.29K | 81.31K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.04 | 0.03 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.87 | -2.01 | 0.33 | -0.59 | -0.47 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ADIL Frequently Asked Questions
What is Adial Pharmaceuticals, Inc. stock symbol ?
Adial Pharmaceuticals, Inc. is a US stock , located in Charlottesville of Va and trading under the symbol ADIL
What is Adial Pharmaceuticals, Inc. stock quote today ?
Adial Pharmaceuticals, Inc. stock price is $2.15 today.
Is Adial Pharmaceuticals, Inc. stock public?
Yes, Adial Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 6.43M
- Market Capitalization 9.45M
- Employee 4
- CEO Mr. Cary John Claiborne MBA
- Headquarters Charlottesville,VA,US
- IPO Date 2018-07-27
-
Website
https://www.adialpharma.com 
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
